Copyright © Inderes 2011 - present. All rights reserved.

Biohit

2.87 EUR

+0.70 %

4,931 following
Corporate customer

BIOBV

NASDAQ Helsinki

Medical Equipment & Services

Health Care

+0.70 %
-15.84 %
-22.22 %
-15.34 %
0.00 %
-3.37 %
+58.56 %
+26.99 %
-44.81 %

Biohit operates in the medical technology sector. The company develops and manufactures laboratory equipment, consumables and diagnostic analysis systems adapted for research, healthcare and industrial laboratories. In addition to its main business, it offers technical support, maintenance and training services within the aforementioned field of work. The largest operations are conducted in the Nordic market. The company has its headquarters in Helsinki.

Read more
Market cap
43.62M EUR
Turnover
15.95K EUR
P/E (adj.) (26e)
19.67
EV/EBIT (adj.) (26e)
13.71
P/B (26e)
2.53
EV/S (26e)
2.12
Dividend yield-% (26e)
1.53 %
Coverage
Recommendation
Accumulate
Target price
3.50 EUR
Updated
2026-02-12
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-02-12

Latest extensive report

Released: 2025-01-15

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
3/6
2026

General meeting '26

5/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
I apologize for the really long message. This is somehow very hard for me to summarize briefly, because otherwise the justifications always remain completely insufficient. I tried hard, but this turned into a long explanation. Or is this starting to resemble the TEM1V pattern (VMBO...
2/15/2026, 6:11 PM
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
16
And it’s no longer just minor friction in receivables. Since Biohit’s impressive turnaround, they have generated a cumulative net profit of just under €8 million on paper during the 2022-2025 financial years. Cash flow tells a slightly different story. I quickly calculated that the...
2/15/2026, 8:04 PM
by JP199
15
This seems to be a case of the so-called Urpilainen “first of all, I would like to remind you of the royalty income from China” Hefei has been paying them. The new contract structure clearly no longer includes licensing income from a certain point onwards. There will surely be an...
yesterday
by Antti Siltanen
13
Phew, wow, and oh my goodness. Huge and most humble thanks to both @JP199 and @Antti_Siltanen !! I admit I was completely in the dark that the situation regarding those receivables is this bad. This is starting to remind me of the TEM1V case one-to-one (1:1). As I have written, I...
yesterday
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
7
At least in my opinion, the analysis (including management interviews) has highlighted this very well, which is why these receivables/cash flow have been monitored closely from the start If a risk materializes in this regard, no one can at least blame Inderes for ignoring the risk
yesterday
by JP199
6
Siltanen interviewed Biohit’s CEO Jussi Hahtela. Inderes Biohit H2'25: Vahva kannattavuus - Inderes Aika: 11.02.2026 klo 15.02 Biohitin liikevaihdon kasvua vauhdittivat Hefei‑sopimuksen jatkamisesta johtuvat rojaltitulot sekä pikatestien vahva myynti. Liikevoitto ylitti ennusteemme...
2/11/2026, 1:50 PM
by Sijoittaja-alokas
6
This really good clarification by @JP199 to my own previous ramblings kept playing on my mind disturbingly. I have hyped up the company’s great openings (UK, India, South Korea, Chile) and their immense potential here. In my opinion, this “ketchup bottle effect” is still real. However...
2 hours ago
by Balle Ramsted - pienehkö kasvusijoittaja nupullaan
5
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.